母细胞样和多形性套细胞淋巴瘤:仍是诊断和治疗挑战!
母细胞样和多形性套细胞淋巴瘤呈高度侵袭性且临床病程差,细胞形态学标准主观,Ki-67 增殖指数可支持诊断并超越细胞学亚型的预后信息。遗传学提示这些变异型与经典型套细胞淋巴瘤不同,约占全部病例的10%。含高剂量阿糖胞苷方案及高剂量巩固可能被推荐,但长期结局仍受损,靶向治疗数据稀缺。
要点
- 母细胞样和多形性变异型约占套细胞淋巴瘤的10%,临床病程高度侵袭。
- Ki-67 指数可超越细胞学亚型提供的预后信息。
- 含高剂量阿糖胞苷方案可能被推荐,但长期结局仍受损。
核心结论
- 母细胞样和多形性套细胞淋巴瘤仍是诊断和治疗挑战,呈高度侵袭性且临床病程差。
- 含高剂量阿糖胞苷方案及高剂量巩固可能被推荐,但即使强化方案长期结局仍受损。
- 靶向治疗数据稀缺,伊布替尼治疗缓解率高但中位缓解持续时间<6个月。
研究设计与样本
- 综述类文章,检索范围原文未报告。
主要发现
- 母细胞样和多形性变异型约占所有套细胞淋巴瘤病例的10%。
- Ki-67 指数超越细胞学亚型提供的预后信息。
- 遗传学分析提示母细胞样和多形性变异型与经典型套细胞淋巴瘤不同。
- 伊布替尼治疗缓解率高,但中位缓解持续时间<6个月。
- 来那度胺和替西罗莫司仅导致短期缓解。
关键数值与推荐
- 母细胞样和多形性变异型由细胞形态学特征定义,但标准有一定主观性。
- 诊断可基于 Ki-67 标记指数的高细胞增殖支持。
- 含高剂量阿糖胞苷方案及高剂量巩固可能被一般推荐。
- 在疾病管理早期可讨论异基因移植。
临床怎么用
- 含高剂量阿糖胞苷方案及高剂量巩固可能被一般推荐。
- 在疾病管理早期可讨论异基因移植。
- 靶向方法在这些患者中有必要,但临床数据稀缺。
局限性
- 细胞形态学标准有一定主观性。
- 这些亚群的频率在临床队列中差异很大。
- 靶向治疗的临床数据稀缺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Blastoid mantle cell lymphoma is characterized by highly aggressive features and a dismal clinical course. These blastoid and pleomorphic variants are defined by cytomorphological features, but the criteria are somewhat subjective. The diagnosis may be supported by a high cell proliferation based on the Ki-67 labeling index. Recent analyses have shown that the Ki-67 index overrules the prognostic information derived from the cytology subtypes. Nevertheless, genetic analysis suggests that blastoid and pleomorphic variants are distinct from classical mantle cell lymphoma. In clinical cohorts, the frequency of these subsets varies widely but probably represents ∼10% of all cases. Chemotherapy regimens commonly used in mantle cell lymphoma, such as bendamustine, rarely achieve prolonged remissions when given at the dosage developed for classical variants of the disease. Thus, high-dose cytarabine-containing regimens with high-dose consolidation may be generally recommended based on the more aggressive clinical course in these patients. However, even with these intensified regimens, the long-term outcome seems to be impaired. Thus, especially in this patient subset, allogeneic transplantation may be discussed at an early time point in disease management. Accordingly, targeted approaches are warranted in these patients, but clinical data are scarce. Ibrutinib treatment results in high rates of responses, but the median duration of remission is <6 months. Similarly, lenalidomide and temsirolimus result in only short-term remissions. Novel approaches, such as chimeric antigenic receptor T cells, may have the potential to finally improve the dismal long-term outcome of these patients.
引用
- Dreyling M, Klapper W, Rule S, et al. Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! Blood. 2018. PMID: 30385481. doi:10.1182/blood-2017-08-737502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。